Skin care composition containing sodium hyaluronate and method of making the same

ABSTRACT

A physically stable skin care composition with a continuous phase and a dispersed phase and a method for making the same. The continuous phase can include from about 0.5% to about 1.5% sodium hyaluronate with a weight average molecular weight from about 500,000 to about 1,000,000 Da according to the European Pharmacopoeia Method. The continuous phase can also include at least two thickening agents that can includes polyacrylamide polymers and copolymers and a carboxylic acid polymer. The dispersed phase can include silicone. The composition can have an average viscosity greater than 25,000 cP and the sodium hyaluronate can be fully hydrated.

FIELD OF THE INVENTION

The present invention is generally directed towards skin carecompositions that contain hyaluronic acid and one or more thickeningagents, in particular a physically stable skin care emulsion compositionthat contains greater than 0.5% hyaluronic acid with a weight averagemolecular weight of from about 200,000 Da to about 1.5 million Da, twothickening agents, and an average viscosity greater than or equal to25,000 cP (25 Pa*s).

BACKGROUND OF THE INVENTION

Many consumers want skin care products that contain sodium hyaluronate,particularly a relatively high level of sodium hyaluronate (e.g., ≥0.5%,≥0.7%, ≥0.9%, or ≥1%). Sodium hyaluronate can increase skin hydrationand reduce the appearance of fine lines and wrinkles.

Some consumers want sodium hyaluronate in a cream/moisturizer intendedfor use on the face, neck, and/or eye area. These products are left onthe skin, where the product can penetrate the skin to help repair, aswell as remain on the surface to help protect skin from the outsideelements.

Creams can be stored and dispensed from a jar. Many consumers like jarsbecause they look great both when they are left out on a vanity orstored in a medicine cabinet, drawer, or shelf. It can also besatisfying for a consumer to scoop the cream out of a jar and apply itacross the face, neck, and/or eye area. The jar's wide mouth also letsthe user see the creamy, luscious texture of the product. Consumeracceptable creams stored in jars need to have sufficient viscosity, sothey do not slosh out of the jar during handling and use.

However, it was found that adding a relatively high level of sodiumhyaluronate to a cream, in particular a cream composition that containedtraditional polymeric thickening agents, according to the typical methodand order of addition for cream/moisturizers at production scaleunexpectedly built an unmanageable level of viscosity. This resulted ina product where the sodium hyaluronate was not fully dispersed, whichnegated the hydration of sodium hyaluronate, and rendered the productunacceptable to consumers.

Therefore, there is a need for a cream/moisturizer that has sufficientviscosity so it can be stored in a jar and contains a relatively highlevel of sodium hyaluronate that is fully hydrated.

SUMMARY OF THE INVENTION

A skin care composition comprising: (a) a continuous phase comprising:(i) from about 0.5% to about 1.5% sodium hyaluronate with a weightaverage molecular weight of from about 500,000 to about 1,000,000 Da,according to the European Pharmacopoeia Method; (ii) from about 0.1% toabout 1% of a carboxylic acid polymer thickening agent; (iii) from about0.8% to about 2.1% of polyacrylamide polymers and copolymer thickeningagent; (iv) water; (b) a dispersed phase comprising silicone; whereinthe sodium hyaluronate is fully hydrated; wherein the compositioncomprises a viscosity greater than 25,000 cP.

BRIEF DESCRIPTION OF THE DRAWINGS

While the specification concludes with claims particularly pointing outand distinctly claiming the subject matter of the present invention, itis believed that the invention can be more readily understood from thefollowing description taken in connection with the accompanyingdrawings, in which:

FIG. 1 shows the impact on viscosity of a simple system when adjustingthe weight average molecular weight of 1% sodium hyaluronate;

FIG. 2 shows a photograph from a first wetting experiment with water andsodium hyaluronate;

FIG. 3 shows a photograph from a second wetting experiment with glycerinand sodium hyaluronate;

FIG. 4 shows the viscosity vs temperature for compositions containingglycerin, silicone(s), emulsifier, and/or sodium hyaluronate; and

FIG. 5 shows a schematic diagram of the production system.

DETAILED DESCRIPTION OF THE INVENTION

Hyaluronic acid is a biological polymer that occurs naturally in theskin and is the natural mucopolysaccharide formed by bondingN-acetyl-O-glucosamine with glucuronic acid. Sodium hyaluronate is thesodium salt of hyaluronic acid and it can be used in skin care productsincluding creams/moisturizers.

Many consumers want skin care compositions that contain sodiumhyaluronate, because it can regulate water within skin's surface cellsand keep skin hydrated throughout the day. The mechanism by whichhyaluronic acid and salts thereof hydrate skin can also help preventfine lines and wrinkles.

Many current marketed skin care compositions include relatively lowlevels of sodium hyaluronate. Some consumers may want skin carecompositions that have a relatively high level (e.g., ≥0.5%, ≥0.7%,≥0.9%, or ≥1%) of sodium hyaluronate, hoping to achieve even moremoisture and/or anti-aging benefits. Many consumers want to apply skincare compositions with sodium hyaluronate in a cream, which generallycontains thickening agents.

However, it can be difficult to formulate a homogenous emulsion wherethe sodium hyaluronate is fully hydrated. It was discovered that ˜1%sodium hyaluronate unexpectedly built viscosity in compositions,especially in compositions with one or more polymeric thickening agents.It was also surprisingly found that the amount of viscosity built wascorrelated with the molecular weight of the sodium hyaluronate.

FIG. 1 shows the impact of the weight average molecular weight (Mw) ofsodium hyaluronate in a simple system comprised of 7% Glycerin, 1%Sodium Hyaluronate, and the balance water on viscosity. FIG. 1 showsthat as the Mw of the sodium hyaluronate increases, the viscosityincreases.

The molecular weights were provided in a certificate of analysis by thesupplier. The average viscosity was measured according to the ViscosityTest Method, described hereafter. The average viscosity was determinedaccording to the following method: the viscosities for the simple systemwere measured after holding the sample for at least 24 hours at about25° C. The viscosities of the examples are measured by a DV2T™-RVviscometer with RV3 spindle rotated at 5 rpm (available from BrookfieldEngineering Laboratories, Middleboro, Massachusetts) at 25° C. Thespindle is fully submerged, 2.5-3.0 cm below the composition's surface.The spindle is rotated for 30 s before starting data collection, thenone data point is collected every 10 seconds for 5 readings, average(mean) the readings to determine the average viscosity.

Next, formulations, as described in Table 1, below, were made toevaluate the product stability and viscosity at different levels ofthickening agent (Polyacrylamide & C13-14 Isoparaffin & Laureth-7commercially available as Sepigel™ 305 from Seppic® Corporation and0.45% Acrylates/C10-30 Alkyl Acrylate Crosspolymer) in combination with1% sodium hyaluronate with different weight average molecular weights.The results are summarized in Table 2, below.

TABLE 1 Material Example (wt. %) Water Phase Water QS SodiumHyaluronate¹ 1 Polyacrylamide and 0.9-1.8 isoparaffin and laureth-7² (asindicated in Table 2) Acrylates/C10-30 Alkyl 0.45 Acrylate Crosspolymer³Glycerin 7 Niacinamide and other skin 2.853 care actives Chelant 0.025Antioxidant 0.15 Preservative 0.25 Emulsifer 0.1 Oil Phase 5 cstDimethicone 4 Dimethicone and 2 Dimethiconol⁴ Emulsifiers 0.4 ¹Theweight average molecular weight was 511,000 Da, 615,000 Da, 855,000 Da,or 920,000 Da, as indicated in Table 2, below. ²Sepigel ™ 305 fromSeppic ® Corporation ³Carbopol ® Ultrez 21 from Lubrizol ® ⁴DC 1503 fromDow Coming ®

The average viscosity was determined ˜24 hours after the cream was madeand after 2 weeks of storage at 60° C. If the average viscosity was lessthan or equal to 25,000 cP (25 Pa*s), as determined according to theViscosity Test Method, after 2 weeks of storage at 60° C., it was notacceptable because it would be too thin to be easily used from a jar, asit would tend to slosh out during handling and use.

The weight average molecular weights of the sodium hyaluronate wereprovided in a certificate of analysis by the supplier.

TABLE 2 Mw of Sodium Hyaluronate 511,000 Da 615,000 Da 855,000 Da920,000 Da Sepigel ™ Initial 2 Weeks Initial 2 Weeks Initial 2 WeeksInitial 2 Weeks 305 Viscosity at 60° C. Viscosity at 60° C. Viscosity at60° C. Viscosity at 60° C. (wt. %) (cP) (cP) (cP) (cP) (cP) (cP) (cP)(cP) 0.9 24000 15000 32000 19000 — — — — 1.2 — — — — 53000 36000 5800033000 1.5 33000 22000 44000 28000 — — — — 1.8 38000 26000 52000 33000 —— — —

Table 2 shows that the average product viscosity increases as theconcentration of Sepigel™ 305 increased, as well as when the Mw of thesodium hyaluronate increased. The compositions containing sodiumhyaluronate with a Mw of 511,000 Da and 0.9% and 1.5% Sepigel™ 305 andthe composition containing sodium hyaluronate with a Mw of 615,000 Da at0.9% Sepigel™ 305 did not have sufficient viscosity after two weeks at60° C. and therefore are not consumer acceptable.

The Sepigel™ 305 dose response curves were not completed for the twohigher Mw sodium hyaluronates (i.e., 855,000 Da and 920,000 Da), sincethe single point average viscosities were higher than that of thecorresponding level of Sepigel™ 305 used with the lower Mw sodiumhyaluronates, based upon the dose response curves. Therefore, it isexpected that the higher MW sodium hyaluronates would have sufficientviscosity soon after they are made and after two weeks of storage at 60°C.

During benchtop production, it was observed that sodium hyaluronate hada greater impact on finished product viscosity than initially expected.To achieve full hydration of sodium hyaluronate when directly added tothe water phase it was found that high shear energy and extended mixtimes were required. If not fully hydrated, gelation balls of sodiumhyaluronate can be present in final product. The gelation balls caneventually hydrate, but the finished product may not be homogenous(i.e., the finished product can contain areas of high and lowconcentrations of sodium hyaluronate, which is not consumer acceptable).The challenge to fully hydrate and disperse sodium hyaluronate isexacerbated as the manufacturing scale is increased from benchtop to theproduction level.

FIG. 2 shows a photograph from a wetting experiment and shows whatappears to be a bead of water 2 sitting on top of sodium hyaluronatepowder 1. From this experiment, it was determined that sodiumhyaluronate's rate of hydration can be instantaneous upon contact withwater. Such instantaneous hydration can cause the sodium hyaluronate tobind and form a barrier around itself (i.e., form gelation balls ofsodium hyaluronate). Typically, water diffuses into polymers; however,sodium hyaluronate's diffusion mechanism is reversed, sodium hyaluronatediffuse into water. It appears in FIG. 2 that a pure bead of water sitsatop the bed of sodium hyaluronate powder, however, over time the sodiumhyaluronate diffuses into the bead of water and the bead of waterbecomes gel like.

It was determined that if sodium hyaluronate were added directly to thewater phase, like most actives, it would take significant time to reachfull hydration (e.g., ˜4 to 24 hours or more for full scale productions,depending on production size). The problems with hydrating sodiumhyaluronate to the water phase were exacerbated because thecream/moisturizer composition had two polymeric thickening agents (i.e.,Sepigel™ 305 and Ultrez 21), which are needed to build sufficientviscosity in the composition, but also function via hydration/swellingin water, which further reduces the amount of free water in the system.

FIG. 3 shows a photograph from a second wetting experiment. FIG. 3 showsa pool of glycerin 3, which diffused into sodium hyaluronate powder 1.In this experiment, the sodium hyaluronate dispersed rapidly into theglycerin. It is believed that other oils, like silicone, would interactwith sodium hyaluronate powder similarly to glycerin. Thus, it wasdetermined that in order to reduce manufacturing time the sodiumhyaluronate could be added to the water phase as part of a pre-mix, inparticular a low water or water-free premix. The preferred premix couldalso have relatively low viscosity, in particular low viscosity withoutheating.

FIG. 4 shows the temperature vs. average viscosity for the Examples 1-4in Table 3, below.

TABLE 3 Ex. 1 Ex. 2 Ex. 3 Ex. 4 (wt. %) (wt. %) (wt. %) (wt. %) 5 cstDimethicone 22.99 45.45 18.35 Dimethicone and 45.45 18.35 Dimethiconol¹Polysorbate 20 4.55 1.835 Laureth 4 2.3 4.55 1.835 Glycerin 74.71 59.63100 ¹DC1503 from Dow Corning ®

As shown in FIG. 4 , the Example 2 curve generally had a lower averageviscosity than glycerin between about 20° C. and 50° C., which indicatedthat silicone may be preferable for a premix over glycerin because ithas a lower average viscosity without being heated, which reduces thetime and energy consumption, which is especially important at largescale production. It is also interesting to note that Example 1, whichincluded silicone and glycerin had an average viscosity dependance morelike glycerin than silicone, and this may also be less preferred than apremix with predominantly silicone. Also, commercially availableglycerin generally has a very small amount of water (˜1-2%) and sincesodium hyaluronate hydrates instantly upon contact with water, it can bepreferred to have a premix that is free of water (e.g., silicone oranother oil).

To make the cream/moisturizer compositions described herein, thefollowing method can be used. First, a water phase is made with watersoluble ingredients including, but not limited to, glycerin, chelant(e.g., disodium EDTA), water soluble skin care actives (e.g.,panthenol), antioxidants (e.g., hydroxyacetophenone). In some examples,a thickening agent that does not swell until the pH of the compositionis increased, like Carbopol® Ultrez 21, can be added to the water phase.FIG. 5 shows a schematic diagram of the production system. The waterphase can be added to main mix tank 10 and stirred with a pitch bladeturbine. The contents of main mix tank 10 can be recirculated by pump 40to ensure bulk homogeneity. Water phase is mixed until the ingredientsare in solution and/or dispersed. The water phase can contain about 70%to about 98%, alternatively from about 75% to about 95%, alternativelyfrom about 80% to about 94%, alternatively from about 85% to about 93%,or alternatively from about 88% to about 92% water. Separately, a premixcan be made. The premix can include the one or more silicones, sodiumhyaluronate and emulsifiers. The premix can be mixed in a tank separatefrom the water phase, like premix tank 20. The sodium hyaluronate can bemixed until it is fully dispersed in the premix. The premix can be about5% to about 35%, alternatively from about 7% to about 30%, alternativelyfrom about 9% to about 25%, alternatively from about 11% to about 21%,or alternatively from about 13% to about 19% sodium hyaluronate.

The premix can be added to the water phase. Then, the mixture is milledto emulsify the silicone premix into the water phase, forming anemulsion where the water phase is the continuous phase, and the siliconedroplets are dispersed in the internal phase. Since sodium hyaluronateis hydrophilic and swellable in water, the dispersed sodium hyaluronateleaves the oil phase during milling/recirculation and comes toequilibrium in the water phase where it can be fully hydrated in water.

In examples where the premix is added to the main mix in line attransfer injection port 50, as shown in FIG. 5 , it was surprisinglyfound that if the premix, which contains sodium hyaluronate, was blendedinto the water phase too quickly, high pressure could build in thesystem, since the full surface area of the hyaluronic acid was exposedand instantly hydrates when it becomes exposed to water. When thepressure in the system is greater than the system pressure rating, thepressure valve releases, and the system stops recirculating. It wasdetermined that the ratio of hyaluronic acid to water can be importantto prevent the pressure from building up too quickly in the system. Whenthe premix and the main mix first meet in line, there is less than 3%,alternatively less than 2.5%, alternatively less than 2.9%,alternatively less than 2.5%, alternatively less than 2.25%,alternatively less than 2.0%, alternatively less than 1.9%,alternatively less than 1.8%, alternatively less than 1.7% sodiumhyaluronate at the transfer injection port. As the sodium hyaluronate isadded to the system, the level of sodium hyaluronate at the transferinjection port increases above the level it when the premix was firstadded. When all the premix is added there can be greater than 1.75%,alternatively greater than 2%, alternatively greater than 2.2%,alternatively greater than 2.4%, alternatively greater than 2.6%,alternatively greater than 2.8%, alternatively greater than 2.85%,alternatively greater than or equal to 2.9%, alternatively greater thanor equal to 2.95% sodium hyaluronate at the transfer injection port.

After the emulsion is formed, the additional ingredients can be added.In some examples, niacinamide can be added. If added, niacinamide canchange the pH and can cause pH sensitive thickening agents (e.g.,Carbopol© Ultrez 21), if present, to swell. Other thickening agents(e.g., Sepigel™ 305), preservatives (e.g., phenoxyethanol), additionalskin care actives (e.g., promatrixyl), pH adjusters (e.g., aminomethylpropanol), emollients (e.g., ethylhexylglycerin), and optionalingredients can also be added.

All percentages are by weight of the cosmetic composition, unlessspecifically stated otherwise. All ratios are weight ratios, unlessspecifically stated otherwise. All ranges are inclusive and combinable.The number of significant digits conveys neither a limitation on theindicated amounts nor on the accuracy of the measurements. All numericalamounts are understood to be modified by the word “about” unlessotherwise specifically indicated. Unless otherwise indicated, allmeasurements are understood to be made at approximately 25° C. and atambient conditions, where “ambient conditions” means conditions underabout 1 atmosphere of pressure and at about 50% relative humidity. Allnumeric ranges are inclusive of narrower ranges; delineated upper andlower range limits are interchangeable to create further ranges notexplicitly delineated.

Definitions

“Effective amount” means an amount of a compound or compositionsufficient to significantly induce a positive benefit to keratinoustissue over the course of a treatment period. The positive benefit maybe a health, appearance, and/or feel benefit, including, independentlyor in combination, the benefits disclosed herein. In a specific example,an effective amount of a vitamin B₃ compound is an amount sufficient toimprove the health and/or appearance of psoriatic skin during atreatment period. In some instances, an effective amount may bedemonstrated using ex vivo and/or in vitro methods.

“Improve the appearance of” means providing a measurable, desirablechange or benefit in skin appearance, which may be quantified, forexample, by a decrease in redness, inflammation, and/or plaque scales.

“Safe and effective amount” means an effective amount of an ingredientthat is low enough to avoid serious side effects (within the scope ofsound medical judgment).

“Skin care” means regulating and/or improving a skin condition. Somenonlimiting examples include improving skin appearance and/or feel byproviding a smoother, more even appearance and/or feel; increasing thethickness of one or more layers of the skin; improving the elasticity orresiliency of the skin; improving the firmness of the skin; and reducingthe oily, shiny, and/or dull appearance of skin, improving the hydrationstatus or moisturization of the skin, improving the appearance of finelines and/or wrinkles, improving skin exfoliation or desquamation,plumping the skin, improving skin barrier properties, improve skin tone,reducing the appearance of redness or skin blotches, and/or improvingthe brightness, radiancy, or translucency of skin.

“Skin care active” means a compound or combination of compounds that,when applied to skin, provide an acute and/or chronic benefit to skin ora type of cell commonly found therein. Skin care actives may regulateand/or improve skin or its associated cells (e.g., improve skinelasticity, hydration, skin barrier function, and/or cell metabolism).

“Skin care composition” means a composition that includes a skin careactive and regulates and/or improves skin condition.

“Treatment period” means the length of time and/or frequency that amaterial or composition is applied to a target skin surface.

Composition

The skin care composition can be a moisturizer/cream with a viscositythat is sufficient for it to be dispensed from a jar without sloshingand is also thin enough so it can be easily spread across a user's face,eye area, and/or neck. The average viscosity can be greater than 25,000cP (25 Pa*s), alternatively greater than or equal to 27,000 cP (27Pa*s), or alternatively greater than or equal to 30,000 cP (30 Pa*s).The average viscosity can be from about 23,000 cP (23 Pa*s) to about75,000 cP (75 Pa*s), alternatively from about 24,000 cP (24 Pa*s) toabout 68,000 cP (68 Pa*s), or alternatively from about 25,000 cP (25Pa*s) to about 60,000 cP (60 Pa*s). The average viscosity can bedetermined by the Viscosity Test Method, described hereafter.

The composition can contain greater than or equal to 0.5%, alternativelygreater than or equal to 0.6%, alternatively greater than or equal to0.7%, alternatively greater than or equal to 0.8%, alternatively greaterthan or equal to 0.9%, or alternatively greater than or equal to 1.0%sodium hyaluronate. The composition can contain from about 0.5% to about5%, alternatively from about 0.6% to about 4%, alternatively from about0.75% to about 3%, alternatively from about 0.9% to about 2%,alternatively from about 1% to about 1.5% sodium hyaluronate.

The sodium hyaluronate can have a Mw of from about 200,000 Da to about1.5 million Da, alternatively from about 300,000 Da to about 1.25million Da, alternatively from about 400,000 Da to about 1 million Da,or alternatively from about 500,000 Da to about 950,000 Da. The sodiumhyaluronate can have a Mw of less than 3 million Da, alternatively lessthan 2 million Da, alternatively less than 1 million Da. The sodiumhyaluronate can have a Mw of greater than 100,000 Da, alternativelygreater than 200,000 Da, alternatively greater than 300,000 Da,alternatively greater than 400,000 Da, alternatively greater than about500,000 Da. The Mw of sodium hyaluronate can be determined according tothe method described in the European Pharmacopoeia (EuropeanPharmacopoeia 9.0. Sodium Hyaluronate. 01/2017).

The skin care composition can contain about 1% sodium hyaluronate with aMw of from about 300,000 Da to about 1 million Da, alternatively fromabout 400,000 Da to about 950,000 Da, alternatively from about 500,000Da to about 920,000 Da, alternatively from about 505,000 Da to about855,000 Da, or alternatively from about 510,000 Da to about 620,000 Daand greater than 1.6% thickening agent, alternatively greater than 1.7%thickening agent, alternatively greater than 1.75% thickening agent, oralternatively greater than or equal to about 1.8% thickening agent.

The skin care composition can contain about 1% sodium hyaluronate with aMw of from about 500,000 Da to about 1 million Da, alternatively fromabout 550,000 Da to about 950,000 Da, alternatively from about 575,000Da to about 920,000 Da, alternatively from about 600,000 Da to about855,000 Da, alternatively from about 610,000 Da to about 800,000,alternatively from about 615,000 Da to about 750,000 Da, oralternatively from about 615,000 Da to about 700,000 Da and greater than1.3% thickening agent, alternatively greater than 1.4% thickening agent,or alternatively greater than or equal to 1.5% thickening agent.

The skin care composition can contain about 1% sodium hyaluronate with aMw of from about 700,000 Da to about 2 million Da, alternatively fromabout 750,000 Da to about 1.5 million Da, alternatively from about800,000 Da to about 1.25 million Da, alternatively from about 825,000 Dato about 1 million Da, alternatively from about 850,000 Da to about950,000 Da, or alternatively from about 855,000 Da to about 920,000 Daand greater than 0.5% thickening agent, alternatively greater than 0.75%thickening agent, greater than 1% thickening agent, greater than 1.1%thickening agent, or alternatively greater than or equal to 1.2%thickening agent.

The skin care composition can be phthalate free, paraben free, dye-free,free of synthetic fragrance, and/or fragrance free.

Thickening Agent

The composition may include one or more thickening agents, alternativelyat least two thickening agents. The compositions may comprise greaterthan 1%, alternatively greater than 1.2%, alternatively greater than1.4%, alternatively greater than 1.5%, alternatively greater than 1.55%,alternatively greater than 1.6%, or alternatively greater than or equalto 1.65% thickening agent. The compositions may comprise less than orequal to 2.5%, alternatively less than or equal to 2.4%, alternativelyless than or equal to 2.3%, or alternatively less than or equal to 2.25%thickening agent. The compositions may comprise from about 1% to about3%, alternatively from about 1.2% to about 2.75%, alternatively fromabout 1.5% to about 2.5%, or alternatively from about 1.6% to about 2.3%of a thickening agent. Suitable classes of thickening agents include butare not limited to carboxylic acid polymers, polyacrylamide polymers,sulfonated polymers, copolymers thereof, hydrophobically modifiedderivatives thereof, and mixtures thereof.

The composition can include a carboxylic acid polymer thickening agentsuch as a carbomer. The composition can contain from about 0.1% to about1%, alternatively from about 0.2% to about 0.8%, alternatively 0.25% toabout 0.7%, alternatively from about 0.3% to about 0.6%, andalternatively from about 0.4% to about 0.5% of a carboxylic acid polymerthickening agent.

The composition can include a polyacrylamide polymer and copolymerthickening agent. The composition can contain from about 0.8% to about2.1%, alternatively from about 0.9% to about 2%, alternatively fromabout 1% to about 1.9%, alternatively from about 1.1% to about 1.8%,alternatively from about 1.2% to about 1.7%, or alternatively from about1.3% to about 1.6% polyacrylamide polymer and copolymer thickeningagent.

Suitable thickening agents include carboxylic acid polymers such as thecarbomers (e.g., the CARBOPOL® 900 series such as CARBOPOL® 954), andUltrez 10 and Ultrez 30. Other suitable carboxylic acid polymeric agentsinclude copolymers of C₁₀₋₃₀ alkyl acrylates with one or more monomersof acrylic acid, methacrylic acid, or one of their short chain (i.e.,C₁₄ alcohol) esters, wherein the crosslinking agent is an allyl ether ofsucrose or pentaerytritol. These copolymers are known asacrylates/C₁₀₋₃₀ alkyl acrylate crosspolymers and are commerciallyavailable as CARBOPOL® 1342, CARBOPOL® 1382, Ultrez 20, Ultrez 21,PEMULEN TR-1, and PEMULEN TR-2, from Noveon, Inc.

Other suitable thickening agents include the polyacrylamide polymers andcopolymers. An exemplary polyacrylamide polymer has the CTFA designation“polyacrylamide and isoparaffin and laureth-7” and is available underthe trade name SEPIGEL 305 from Seppic® Corporation (Fairfield, N.J.).Other polyacrylamide polymers useful herein include multi-blockcopolymers of acrylamides and substituted acrylamides with acrylic acidsand substituted acrylic acids. Commercially available examples of thesemulti-block copolymers include HYPAN SR150H, SS500V, SS500 W, SSSA100H,from Lipo Chemicals, Inc., (Patterson, N.J.).

Other suitable thickening agents useful herein are sulfonated polymerssuch as the CTFA designated sodium polyacryloyldimethyl taurateavailable under the trade name Simulgel 800 from Seppic® Corp. andViscolam® at 100 P available from Lamberti S.p.A. (Gallarate, Italy).Another commercially available material comprising a sulfonated polymeris Sepiplus™ 400 available from Seppic® Corp.

Further, suitable thickening agents may include superabsorbent polymers.These superabsorbent polymers may be chosen from: crosslinked sodiumpolyacrylates, such as, for example, those sold under the names OctacareX100, X110 and RM100 by Avecia®, those sold under the names FlocareGB300 and Flosorb 500 by SNF™, those sold under the names Luquasorb1003, Luquasorb 1010, Luquasorb 1280 and Luquasorb 1100 by BASF@, thosesold under the names Water Lock G400 and G430 (INCI name:Acrylamide/Sodium Acrylate Copolymer) by Grain Processing@, or AquaKeep® 10 SH NF, Aqua Keep® 10 SH NFC, sodium acrylate crosspolymer-2,provided by Sumitomo Seika, starches grafted by an acrylic polymer(homopolymer or copolymer) and in particular by sodium polyacrylate,such as those sold under the names Sanfresh ST-100C, ST100MC andIM-300MC by Sanyo Chemical Industries@, Makimousse 12 and Makimouse 25supplied by Kobo Products Inc (INCI name: Sodium Polyacrylate Starch),hydrolysed starches grafted by an acrylic polymer (homopolymer orcopolymer), in particular the acryloacrylamide/sodium acrylatecopolymer, such as those sold under the names Water Lock A-240, A-180,B-204, D-223, A-100, C-200 and D-223 by Grain Processing@ (INCI name:Starch/Acrylamide/Sodium Acrylate Copolymer). Preferred superabsorbentpolymers can include Makimousse 12 and Makimousse 25.

Suitable thickening agents for use herein include gums. “Gum” is abroadly defined term in the art. Gums include acacia, agar, algin,alginic acid, ammonium alginate, amylopectin, calcium alginate, calciumcarrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guargum, guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid,hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum,kelp, locust bean gum, natto gum, potassium alginate, potassiumcarrageenan, propylene glycol alginate, sclerotium gum, sodiumcarboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum,derivatives thereof and mixtures thereof.

Natural gums are polysaccharides of natural origin, capable of causing alarge viscosity increase in solution, even at small concentrations. Theycan be used as thickening agents, gelling agents, emulsifying agents,and stabilizers. Most often these gums are found in the woody elementsof plants or in seed coatings. Natural gums can be classified accordingto their origin. They can also be classified as uncharged or ionicpolymers (polyelectrolytes), examples of which include the following.Natural gums obtained from seaweeds, such as: agar; alginic acid; sodiumalginate; and carrageenan. Natural gums obtained from non-marinebotanical resources include: gum arabic, from the sap of Acacia trees;gum ghatti, from the sap of Anogeissus trees; gum tragacanth, from thesap of Astragalus shrubs; karaya gum, from the sap of Sterculia trees.Examples of uncharged gums include: guar gum, from guar beans, locustbean gum, from the seeds of the carob tree; beta-glucan, from oat orbarley bran; chicle gum, an older base for chewing gum obtained from thechicle tree; dammar gum, from the sap of Dipterocarpaceae trees;glucomannan from the konjac plant; mastic gum, a chewing gum fromancient Greece obtained from the mastic tree; psyllium seed husks, fromthe Plantago plant; spruce gum, a chewing gum of American Indiansobtained from spruce trees; tara gum, from the seeds of the tara tree.Natural gums produced by bacterial fermentation include gellan gum andxanthan gum.

Vitamin B₃ compound

The compositions herein can include a safe and effective amount of avitamin B₃ compound. In some instances, the present compositions maycontain 0.01% to 10%, by weight, of the vitamin B₃ compound, based onthe weight or volume of the composition (e.g., 0.1% to 10%, 0.5% to 5%,or even 1% to 3%).

As used herein, “vitamin B₃ compound” means a compound having theformula:

Where: R is CONH₂ (i.e., niacinamide), COOH (i.e., nicotinic acid) orCH₂OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of anyof the foregoing.

Exemplary derivatives of vitamin B3 compounds include nicotinic acidesters, including non-vasodilating esters of nicotinic acid (e.g.,tocopheryl nicotinate, myristyl nicotinate) nicotinamide riboside,nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids,nicotinic acid N-oxide, and niacinamide N-oxide.

Dermatologically Acceptable Carrier

The compositions herein include a dermatologically acceptable carrier(which may be referred to as a “carrier”). The phrase “dermatologicallyacceptable carrier” means that the carrier is suitable for topicalapplication to the keratinous tissue, has good aesthetic properties, iscompatible with the actives in the composition, and will not cause anyunreasonable safety or toxicity concerns. In one embodiment, the carrieris present at a level of from about 50% to about 99%, about 60% to about98%, about 70% to about 98%, or, alternatively, from about 80% to about95%, by weight of the composition.

The carrier can be in a wide variety of forms. In some instances, thesolubility or dispersibility of the components (e.g., extracts,sunscreen active, additional components) may dictate the form andcharacter of the carrier. Non-limiting examples include simple solutions(e.g., aqueous or anhydrous), dispersions, emulsions, and solid forms(e.g., gels, sticks, flowable solids, or amorphous materials). In someinstances, the dermatologically acceptable carrier is in the form of anemulsion that has a continuous aqueous phase (e.g., an oil-in-water orwater-in-oil-in-water emulsion) or a continuous oil phase (e.g.,water-in-oil or oil-in-water-in-oil emulsion). The oil phase of theemulsion may include silicone oils, non-silicone oils such ashydrocarbon oils, esters, ethers, and mixtures thereof. The aqueousphase may include water and water-soluble ingredients (e.g.,water-soluble moisturizing agents, conditioning agents, anti-microbials,humectants and/or other skin care actives). In some instances, theaqueous phase may include components other than water, including but notlimited to water-soluble moisturizing agents, conditioning agents,anti-microbials, humectants and/or other water-soluble skin careactives. In some instances, the non-water component of the compositioncomprises a humectant such as glycerin and/or other polyol(s). Thecomposition can contain from about 1% to about 15%, alternatively fromabout 3% to about 10%, alternatively from about 4% to about 9%, andalternatively from about 5% to about 8% humectant.

In some instances, the compositions herein are in the form of anoil-in-water (“O/W”) emulsion that provides a sensorial feel that islight and non-greasy. Suitable O/W emulsions herein may include acontinuous aqueous phase of more than 50% by weight of the composition,and the remainder being the dispersed oil phase. The aqueous phase mayinclude 1% to 99% water, based on the weight of the aqueous phase, alongwith any water soluble and/or water miscible ingredients. In theseinstances, the dispersed oil phase will typically be present at lessthan 30% by weight of composition (e.g., 1% to 20%, 2% to 15%, 3% to12%, 4% to 10%, or even 5% to 8%) to help avoid some of the undesirablefeel effects of oily compositions. The oil phase may include one or morevolatile and/or non-volatile oils (e.g., botanical oils, silicone oils,and/or hydrocarbon oils). Some nonlimiting examples of oils that may besuitable for use in the present compositions are disclosed in U.S. Pat.No. 9,446,265 and U.S. Publication No. 2015/0196464.

The carrier may contain one or more dermatologically acceptablediluents. As used herein, “diluent” refers to materials in which theskin care actives herein can be dispersed, dissolved, or otherwiseincorporated. Some non-limiting examples of hydrophilic diluents includewater, organic hydrophilic diluents such as lower monovalent alcohols(e.g., C₁-C₄) and low molecular weight glycols and polyols, includingpropylene glycol, polyethylene glycol (e.g., molecular weight of 200 to600 g/mole), polypropylene glycol (e.g., Mw of 425 to 2025 g/mole),glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol esters,1,2,6-iexanetriol, ethanol, isoprop anol, sorbitol esters, butanediol,ether propanol, ethoxylated ethers, propoxylated ethers and combinationsthereof.

Silicone Oil

The composition can include a silicone oil selected from volatilesilicone oil, non-volatile silicone oil, and combinations thereof. Thesilicone oil can be in the dispersed phase. The composition can includefrom about 1% to about 10% silicone oil, alternatively from about 3% toabout 8% silicone oil, and alternatively from about 4% to about 7%silicone oil.

Volatile Silicone Oil

Suitable volatile silicones include cyclic and linear volatilesilicones. A description of various volatile silicones is found in Todd,et al. “Volatile Silicone Fluids for Cosmetics”, 91 Cosmetics andToiletries 27-32 (1976). Suitable cyclic volatile silicones includecyclic dimethyl siloxane chains containing an average of from about 3 toabout 5 silicon atoms, preferably from about 4 to about 5 silicon atoms.Exemplary cyclic volatile silicones of varying viscosities include DowCorning DC 244, DC 245, DC 344, and DC 345; GE Silicones-OSi SpecialtiesVolatile Silicone 7207 and Volatile Silicone 7158; and GE SiliconesSF1202. Suitable volatile linear silicones include thepolydimethylsiloxanes containing an average of from about 2 to about 8silicon atoms. Exemplary linear volatile silicones include the DowCorning DC 200 series with viscosities of 0.65 est, 1.0 cst, and 2.0cst. In certain embodiments, the linear volatile silicones generallyhave viscosities of less than or equal to about 4 centistokes at 25° C.,and the cyclic materials generally have viscosities of less than about 6centistokes at 25° C.

Non-Volatile Silicone Oils

Suitable non-volatile silicone oils include polysiloxanes. Non-volatilepolylsiloxanes may have a viscosity of from about 10 to about 1,000,000centistokes at 25° C. Such polysiloxanes can be represented by thegeneral chemical formula:

R3SiO[R2SiO]×SiR3

wherein each R is independently selected from hydrogen or C1-30 straightor branched chain, saturated or unsaturated alkyl, phenyl or aryl,trialkylsiloxy; and x is an integer from 0 to about 10,000. In certainembodiments, R is methyl or ethyl. Commercially available polysiloxanesinclude the polydimethylsiloxanes, which are also known as dimethicones,examples of which include the DM-Fluid series from Shin-Etsu, theVicasil® series sold by Momentive Performance Materials Inc., and theDow Corning® 200 series sold by Dow Corning Corporation. Specificexamples of suitable polydimethylsiloxanes include Dow Corning® 200fluids (also sold as Xiameter® PMX-200 Silicone Fluids). Suitabledimethicones include those represented by the chemical formula:

R3SiO[R2SiO]×[RR′SiO]ySiR3

wherein R and R′ are each independently hydrogen or C1-30 straight orbranched chain, saturated or unsaturated alkyl, aryl, or trialkylsiloxy;and x and y are each integers of 1 to 1,000,000. Examples include alkyldimethicones wherein at least R′ is a fatty alkyl (e.g., C12-22). Asuitable alkyl dimethicone is cetyl dimethicone, wherein R′ is astraight C16 chain and R is methyl, commercially available as2502Cosmetic Fluid from Dow Corning.

Preferred non-volatile oils include dimethicones(polydimethylsiloxanes), preferably with viscosities of between 10 cstand 1000 cst, more preferably between 15 cst to 400 cst, most preferablybetween 20 cst and 200 cst. The average chain lengths for thesepreferred dimethicone materials is from about 12 to about 375dimethylsiloxane units, more preferably from about 20 to about 200dimethylsiloxane units, and most preferably with average chain lengthsof from about 27 to about 125 dimethylsiloxane units. In one embodiment,the second composition will comprise at least one non-volatile siliconeoil. In one such embodiment, at least about 70%, by weight of thenon-volatile oil, is a non-volatile silicone oil. In another embodiment,at least about 80%, by weight of the nonvolatile oil, is a non-volatilesilicone. In yet another embodiment, at least about 90%, by weight ofthe non-volatile oil, is a non-volatile silicone oil.

Other Optional Ingredients

The present composition may optionally include one or more additionalingredients commonly used in cosmetic compositions (e.g., colorants,skin care actives, anti-inflammatory agents, sunscreen agents,emulsifiers, buffers, rheology modifiers, combinations of these and thelike), provided that the additional ingredients do not undesirably alterthe skin health or appearance benefits provided by the presentcompositions. The additional ingredients, when incorporated into thecomposition, should be suitable for use in contact with human skintissue without undue toxicity, incompatibility, instability, allergicresponse, and the like. Some nonlimiting examples of additional activesinclude vitamins, minerals, peptides and peptide derivatives, sugaramines, sunscreens, oil control agents, particulates, flavonoidcompounds, hair growth regulators, anti-oxidants and/or anti-oxidantprecursors, preservatives, protease inhibitors, tyrosinase inhibitors,anti-inflammatory agents, moisturizing agents, exfoliating agents, skinlightening agents, sunless tanning agents, lubricants, anti-acneactives, anti-cellulite actives, chelating agents, anti-wrinkle actives,anti-atrophy actives, phytosterols and/or plant hormones, N-acyl aminoacid compounds, antimicrobials, and antifungals. In some examples, thecomposition can include a fragrance, in particular a natural fragrance,or a colorant, in particular a natural colorant. Other non-limitingexamples of additional ingredients and/or skin care actives that may besuitable for use herein are described in U.S. Publication Nos.2002/0022040; 2003/0049212; 2004/0175347; 2006/0275237; 2007/0196344;2008/0181956; 2008/0206373; 2010/00092408; 2008/0206373; 2010/0239510;2010/0189669; 2010/0272667; 2011/0262025; 2011/0097286; US2012/0197016;2012/0128683; 2012/0148515; 2012/0156146; and 2013/0022557; and U.S.Pat. Nos. 5,939,082; 5,872,112; 6,492,326; 6,696,049; 6,524,598;5,972,359; and 6,174,533.

When including optional ingredients in the compositions herein, it maybe desirable to select ingredients that do not form complexes orotherwise undesirably interact with other ingredients in thecomposition, especially pH sensitive ingredients like niacinamide,salicylates and peptides. When present, the optional ingredients may beincluded at amounts of from 0.0001% to 50%; from 0.001% to 20%; or evenfrom 0.01% to 10% (e.g., 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%,0.5% or 0.1%), by weight of the composition.

Method of Use

The skin care cream/moisturizer composition may be applied to the face,neck, and/or a portion or combination thereof at least once a day, twicea day, or on a more frequent daily basis, during a treatment period.When applied twice daily, the first and second applications areseparated by at least 1 to 12 hours. Typically, the composition isapplied in the morning and/or at night before bed. The treatment periodherein is ideally of sufficient time for the sodium hyaluronate and/orother skin care actives to improve the appearance of the skin. Thetreatment period may last for at least 1 week (e.g., about 2 weeks, 4weeks, 8 weeks, or even 12 weeks). In some instances, the treatmentperiod will extend over multiple months (i.e., 3-12 months). In someinstances, the composition may be applied most days of the week (e.g.,at least 4, 5 or 6 days a week), at least once a day or even twice a dayduring a treatment period of at least 2 weeks, 4 weeks, 8 weeks, or 12weeks.

The cream can be intended for use before bedtime and/or in the morning.It can be evenly massaged over the entire face (including or excludingthe eye area) and/or neck. The product can be the final step in a skincare routine and can be applied after cleansing and optionally afterapplying serums and/or other skin care products.

The cream can be intended to help improve the appearance of fine linesand wrinkles around a user's eyes. The cream can be used in the morningand/or at night and can be gently massaged until thoroughly absorbedinto the eye area—under eyes, outer corners, and/or eyelids.

The cream can be stronger and last longer, up to two times longer thanother commercially available products. The cream can leave skin dewy andhydrated.

Examples

The example in Table 4, can be prepared according to the methoddescribed herein.

Ex. A Ex. B Ex. C Ex. D Ex. E Ex. F Ex. G Water Phase Water QS QS QS QSQS QS QS Dex-Panthenol 0.5 0.5 0.5 — — — 0.5 Glycerin 7 10 — 3 — 7 15Butylene Glycol — — 4 — — — — Disodium EDTA 0.05 0.025 0.05 0.025 0.025— 0.05 Hydroxyacetophenone 0.15 0.15 0.05 — 0.15 — 0.2Ethylhexylglycerine 0.2 0.1 — — — — — Phenoxyethanol 0.05 0.25 0.5 —0.15 — 0.2 Symdiol 68¹ — — — 0.4 — — — Glycacil L² — — — 0.09 — — —Glydant Plus Liquid³ — — — — — 0.3 — Niacinamide 2.0 2.0 5.0 3.5 — 2.03.0 Sepiwhite MSH⁴ — — — — 1.0 — — Glyco-Repair⁵ — — 2.0 — 1.0 — —Palestrina⁶ 0.6 — 0.4 — 1.0 — — Olivem 460⁷ 0.1 — — 0.1 — — —Promatrixyl⁸ 0.4 — 0.7 0.05 — — 0.3 Green Tea Extract — — — — — 1.0 1.0pH Adjustor Triethanolamine 0.45 — 0.1 — — — — Aminomethyl — 0.35 — 0.1— 0.1 — Propanol Thickener Sepigel 305⁹ 0.9 1.5 2.0 — 0.9 1.5 — SimulgelINS-100¹⁰ — — — 0.9 — — 2.0 Makimousse-12¹¹ — — — — 0.5 — 0.5Ultrez-10¹² 0.2 — 0.1 0.1 — 0.1 — Ultrez-21¹³ — 0.45 — 0.1 — 0.1 —Xanthan Gum — — — — — 0.1 0.1 Oil Phase Sodium Hyaluronate 0.5 1.5 1.00.75 1.0 1.0 0.5 Cyclomethicone D5 4.0 1.0 2.0 — — — — Dimethicone 2 cst2.0 — 2.0 — — — — Dimethicone 5 cst 5.0 3.0 4.0 2.0 Dimethicone 50 cst2.0 3.0 2.0 — Dimethicone 350 cst — — 1.0 — — — — DC9041¹⁴ 0.5 — — 1.0 —— 2.0 Hexyldecanol — — — 0.1 5.0 — — Retinyl Propionate 0.3 — — 0.3 — —— Laureth-4 0.1 0.2 0.3 — 0.2 0.1 0.3 DC1503¹⁵ — 2.0 — — 1.5 — —Polysorbate 20 0.1 0.2 — 0.3 0.2 0.2 — ¹1,2-hexanediol and caprylylglycol, from Symrise ® ²Iodopropynyl butylcarbamate, PEG-4 laurate,PEG-4 dilaurate, and polyethylene glycol, from Lonza ® ³DMDM Hydantoin,Butane-1,3-diol, iodopropynyl butylcarbamate, water, from Lonza ®⁴Undecylenoyl phenylalanine, from Seppic ® Corporation ⁵Water andhydrolyzed ceratonia siliqua seed extract, from Silab ® ⁶Water,glycerin, decyl glucoside, lactic acid, benzyl alcohol, and palmitoyldipeptide-7, from Sederma ® ⁷Sodium PEG-7 olive oil carboxylate, fromB&T S.r.l. ⁸Water, glycerin, PEG-100 stearate, benzyl alcohol, andpalmitoyl pentapeptide-4, from Sederma ⁹Polyacrylamide, C13-14Isoparaffin, and laureth-7, from Seppic ® Corporation ¹⁰Sodiumpolyacrylate starch, from Kobo ® Products Inc. ¹²Carbomer, fromLubrizol ® ¹³Acrylates C10-30 alkyl acrylate crosspolymer, fromLubrizol ® ¹⁴Dimethicone (and) dimethicone crosspolymer, from DowCorning ® ¹⁵Dimethicone (and) dimethiconol, from Dow Corning ®

TEST METHODS Viscosity Test Method

After storing for at least 24 hours at 25° C., the product viscosity ismeasured by a DV2T-RV viscometer (available from Brookfield EngineeringLaboratories, Middleboro, Massachusetts) with a TC spindle rotated at 5rpm at 25° C. The spindle starts 2.5-3.0 cm below the product surfaceand travels a helipath downward and collects one reading every 9 secondsfor 5 readings. The average (mean) of the readings is calculated todetermine the average viscosity.

Combinations

A. A skin care composition comprising:

-   -   a. a continuous phase comprising:        -   i. from about 0.5% to about 1.5% sodium hyaluronate with a            weight average molecular weight of from about 500,000 to            about 1,000,000 Da, according to the European Pharmacopoeia            Method;        -   ii. from about 0.1% to about 1% of a carboxylic acid polymer            thickening agent;        -   iii. from about 0.8% to about 2.1% of polyacrylamide            polymers and copolymer thickening agent;        -   iv. water;    -   b. a dispersed phase comprising silicone;        -   wherein the sodium hyaluronate is fully hydrated;        -   wherein the composition comprises an average viscosity            greater than 25,000 cP, according to the Viscosity Test            Method.

B. The composition according to Paragraph A, wherein the composition isphysically stable.

C. The composition according to Paragraph B, wherein the composition ishomogenous.

D. The composition according to Paragraphs A-C, wherein the weightaverage molecular weight of the sodium hyaluronate is from about 500,000Da to about 920,000 Da, more preferably from about 505,000 Da to about855,000 Da, and even more preferably from about 510,000 Da to about620,000, according to the European Pharmacopoeia Method.

E. The composition according to Paragraphs A-D, wherein the weightaverage molecular weight of the sodium hyaluronate is from about 700,000Da to about 1,000,000 Da, preferably from about 750,000 Da to about1,000,000 Da, more preferably from about 800,000 Da to about 1,000,000Da, and even more preferably from about 855,000 Da to about 920,000 Da,according to the European Pharmacopoeia Method.

F. The composition according to Paragraphs A-E, wherein the averageviscosity is greater than or equal to 27,000 cP (27 Pa*s), andpreferably greater than or equal to 30,000 cP (30 Pa*s), according tothe Viscosity Test Method, herein.

G. The composition according to Paragraphs A-E, wherein the averageviscosity is from about 25,000 cP (25 Pa*s) to about 75,000 cP (75Pa*s), preferably from about 25,000 cP (25 Pa*s) to about 68,000 cP (68Pa*s), and more preferably from about 25,000 cP (25 Pa*s) to about60,000 cP (60 Pa*s) according to the Viscosity Test Method, herein.

H. The composition according to Paragraphs A-G, wherein the compositionis free of phthalate, paraben, dye, synthetic fragrance, and/orfragrance.

I. The composition according to Paragraphs A-H, wherein the water phasefurther a vitamin B₃ compound selected from niacinamide, nicotinic acid,nicotinyl alcohol, and combinations thereof

J. The composition according to Paragraphs A-I, wherein the continuousphase further comprises from about 3% to about 10% glycerin, preferablyfrom about 4% to about 9% glycerin, and more preferably from about 5% toabout 8% glycerin.

K. The composition according to Paragraphs A-J, wherein thepolyacrylamide polymers and copolymer thickening agent comprisesPolyacrylamide & C13-14 Isoparaffin & Laureth-7.

L. The composition according to Paragraphs A-K, wherein the carboxylicacid polymer thickening agent comprises Acrylates/C10-30 Alkyl AcrylateCrosspolymer.

M. The composition according to Paragraphs A-L, wherein the compositioncomprises from about 0.2% to about 0.8% of a carboxylic acid polymerthickening agent, preferably from about 0.25% to about 0.7% of acarboxylic acid polymer thickening agent, more preferably from about0.3% to about 0.6% of a carboxylic acid polymer thickening agent, andmost preferably from about 0.4% to about 0.5% of a carboxylic acidpolymer thickening agent.

N. T The composition according to Paragraphs A-N, wherein thecomposition comprises from about 0.9% to about 2% polyacrylamide polymerand copolymer thickening agent, preferably from about 1% to about 1.9%polyacrylamide polymer and copolymer thickening agent, more preferablyfrom about 1.1% to about 1.8% polyacrylamide polymer and copolymerthickening agent, even more preferably from about 1.2% to about 1.7%polyacrylamide polymer and copolymer thickening agent, and mostpreferably from about 1.3% to about 1.6% polyacrylamide polymer andcopolymer thickening agent.

O. A skin care product comprising a jar adapted for storing the skincare composition according to Paragraphs A-N.

P. Use of the skin care serum composition of Paragraphs A-N to increaseskin hydration and/or reduce the appearance of fine lines or wrinkles.

Q. A method for making the skin care composition according to ParagraphsA-N comprising:

-   -   a. preparing a homogenous main mix comprising a carboxylic acid        polymer thickening agent and from about 70% to about 98% water,        preferably from about 75% to about 95%, more preferably from        about 80% to about 94%, and most preferably from about 85% to        about 93%;    -   b. preparing a premix comprising silicone and from about 5% to        about 35% sodium hyaluronate, preferably from about 7% to about        30%, more preferably from about 9% to about 25%, even more        preferably from about 11% to about 21%, and most preferably from        about 13% to about 19% sodium hyaluronate;    -   c. adding the premix to the main mix and milling the mixture to        emulsify the silicone premix into the main mix to form an        emulsion;    -   d. adding a polyacrylamide polymer and copolymer thickening        agent to the emulsion to form a fully hydrated, physically        stable skin care composition comprising a viscosity greater than        25,000 cP.

R. The method according to Paragraph Q, wherein the method is performedwithout adding heat.

S. The method according to Paragraphs Q-R, wherein the main mix furthercomprises glycerin.

T. The method according to Paragraphs Q-S, wherein the premix issubstantially free of water, preferably free of water.

U. The method according to Paragraphs Q-T, wherein the physically stableskin care composition is homogenous.

V. The method according to Paragraphs Q-U, wherein the premix is addedto the main mix in line at a transfer injection port.

W. The method according to Paragraphs Q-V, wherein the amount of sodiumhyaluronate in line at the transfer injection port when the premix andmain mix first meet is less than 2% sodium hyaluronate, preferably lessthan 1.9% sodium hyaluronate, more preferably less than 1.8% sodiumhyaluronate, and most preferably less than 1.7% sodium hyaluronate.

X. The method according to Paragraphs Q-W, wherein one or moreadditional ingredients are added to the emulsion; wherein the additionalingredients selected from vitamin B₃ compound, preservative, additionalskin care active, pH adjuster, emollient, and combinations thereof.

Y. The method according to Paragraphs Q-X, wherein the additionalingredient comprises a vitamin B₃ compound selected from niacinamide,nicotinic acid, nicotinyl alcohol, and combinations thereof is added tothe emulsion.

The dimensions and values disclosed herein are not to be understood asbeing strictly limited to the exact numerical values recited. Instead,unless otherwise specified, each such dimension is intended to mean boththe recited value and a functionally equivalent range surrounding thatvalue. For example, a dimension disclosed as “40 mm” is intended to mean“about 40 mm.”

Every document cited herein, including any cross referenced or relatedpatent or application and any patent application or patent to which thisapplication claims priority or benefit thereof, is hereby incorporatedherein by reference in its entirety unless expressly excluded orotherwise limited. The citation of any document is not an admission thatit is prior art with respect to any invention disclosed or claimedherein or that it alone, or in any combination with any other referenceor references, teaches, suggests or discloses any such invention.Further, to the extent that any meaning or definition of a term in thisdocument conflicts with any meaning or definition of the same term in adocument incorporated by reference, the meaning or definition assignedto that term in this document shall govern.

While particular embodiments of the present invention have beenillustrated and described, it would be obvious to those skilled in theart that various other changes and modifications can be made withoutdeparting from the spirit and scope of the invention. It is thereforeintended to cover in the appended claims all such changes andmodifications that are within the scope of this invention.

1. A skin care composition comprising: a. a continuous phase comprising:i. from about 0.5% to about 1.5% sodium hyaluronate with a weightaverage molecular weight of from about 500,000 to about 1,000,000 Da;ii. from about 0.1% to about 1% of a carboxylic acid polymer thickeningagent; iii. from about 0.8% to about 2.1% of a polyacrylamide polymerand copolymer thickening agent; iv. water b. a dispersed phasecomprising silicone; wherein the sodium hyaluronate is fully hydrated;wherein the composition comprises an average viscosity greater than25,000 cP.
 2. The composition of claim 1, wherein the composition isphysically stable.
 3. The composition of claim 1, wherein thecomposition is homogenous.
 4. The composition of claim 1, wherein thecomposition is free of phthalate, paraben, dye, synthetic fragrance,and/or fragrance.
 5. The composition of claim 1, wherein the sodiumhyaluronate comprises a weight average molecular weight from about700,000 to about 1,000,000 Da.
 6. The composition of claim 1, whereinthe water phase further a vitamin B₃ compound selected from niacinamide,nicotinic acid, nicotinyl alcohol, and combinations thereof
 7. Thecomposition of claim 1, wherein the continuous further comprises fromabout 3% to about 10% glycerin.
 8. The composition of claim 1, whereinthe polyacrylamide polymer and copolymer thickening agent comprisesPolyacrylamide & C13-14 Isoparaffin & Laureth-7.
 9. The composition ofclaim 1, wherein the carboxylic acid polymer thickening agent comprisesAcrylates/C10-30 Alkyl Acrylate Crosspolymer.
 10. A skin care productcomprising a jar adapted for storing the skin care composition ofclaim
 1. 11. A method for making a physically stable skin carecomposition comprising: a. preparing a homogenous main mix comprisingfrom about 0.1% to about 1% of a carboxylic acid polymer thickeningagent and water; b. preparing a premix comprising silicone and fromabout 5% to about 35% sodium hyaluronate; c. adding the premix to themain mix and milling the mixture to emulsify the silicone premix intothe main mix to form an emulsion; d. adding a polyacrylamide polymer andcopolymer thickening agent to the emulsion to form a fully hydrated,physically stable skin care composition comprising an average viscositygreater than 25,000 cP.
 12. The method of claim 11, wherein the methodis performed without adding heat.
 13. The method of claim 11, whereinthe main mix further comprises glycerin.
 14. The method of claim 11,wherein the premix is substantially free of water or free of water. 15.The method of claim 11, wherein the physically stable skin carecomposition is homogenous.
 16. The method of claim 11, wherein thepremix comprises from about 9% to about 25% sodium hyaluronate.
 17. Themethod of claim 11, wherein the premix is added to the main mix in lineat a transfer injection port.
 18. The method of claim 17, wherein theamount of sodium hyaluronate in line at the transfer injection port whenthe premix and main mix first meet is less than 2%.
 19. The method ofclaim 11, wherein one or more additional ingredients are added to theemulsion; wherein the additional ingredients are selected from vitaminB₃ compound, preservative, additional skin care active, pH adjuster,emollient, and combinations thereof.
 20. The method of claim 19, whereinthe additional ingredient comprises a vitamin B₃ compound selected fromniacinamide, nicotinic acid, nicotinyl alcohol, and combinations thereofis added to the emulsion.